MRK 1

Drug Profile

MRK 1

Alternative Names: CCR5 antagonists - Merck; Merck compound A

Latest Information Update: 30 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Amino acids; Antiretrovirals; Pyrazoles
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV-1 infections; Transplant rejection

Most Recent Events

  • 10 Sep 2004 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
  • 10 Sep 2004 Preclinical trials in Transplant rejection in USA (unspecified route)
  • 10 Sep 2004 Data presented at the 228th American Chemical Society National Meeting - (228th-ACS-2004) have been added to the Transplant Rejection pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top